Sunesis Pharmaceuticals, Inc.
(NASDAQ : SNSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.20%128.340.0%$1287.67m
OCGNOcugen, Inc. -18.12%8.570.0%$1027.42m
NVAXNovavax, Inc. -18.78%149.1392.9%$585.78m
AMGNAmgen, Inc. -0.93%221.861.3%$543.86m
VRTXVertex Pharmaceuticals, Inc. -0.80%206.771.9%$514.71m
REGNRegeneron Pharmaceuticals, Inc. -0.42%444.842.7%$501.06m
GILDGilead Sciences, Inc. 1.12%63.451.0%$485.42m
ILMNIllumina, Inc. -4.23%398.803.5%$456.33m
ALXNAlexion Pharmaceuticals, Inc. -0.41%147.582.0%$340.12m
BIIBBiogen, Inc. -0.86%264.321.7%$317.68m
CRSPCRISPR Therapeutics AG -6.08%111.840.6%$265.73m
BNGOBionano Genomics, Inc. -21.64%6.700.0%$236.95m
EXASEXACT Sciences Corp. -6.30%118.6018.4%$221.18m
SGENSeagen Inc. -1.87%145.175.8%$205.12m
PACBPacific Biosciences of California, Inc. -8.32%28.397.2%$150.20m

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.